Dataset Information

Adjuvant Secretomes - Adjuvant-induced human monocyte secretome profiles reveal adjuvant- and age-specific protein signatures

ABSTRACT: Adjuvant-induced human monocyte secretome profiles reveal adjuvant- and age-specific protein signatures.

INSTRUMENT(S): Q Exactive

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Blood Cell, Blood

DISEASE(S): Disease Free

SUBMITTER: Sebastian Berger

LAB HEAD: Hanno Steen, Ofer Levy

PROVIDER: PXD003534 | Pride | 2016-03-14

REPOSITORIES: Pride

ACCESS DATA

Publications

Adjuvant-induced Human Monocyte Secretome Profiles Reveal Adjuvant- and Age-specific Protein Signatures.

Oh Djin-Ye DY Dowling David J DJ Ahmed Saima S Choi Hyungwon H Brightman Spencer S Bergelson Ilana I Berger Sebastian T ST Sauld John F JF Pettengill Matthew M Kho Alvin T AT Pollack Henry J HJ Steen Hanno H Levy Ofer O

Molecular & cellular proteomics : MCP 20160301 6

Adjuvants boost vaccine responses, enhancing protective immunity against infections that are most common among the very young. Many adjuvants activate innate immunity, some via Toll-Like Receptors (TLRs), whose activities varies with age. Accordingly, characterization of age-specific adjuvant-induced immune responses may inform rational adjuvant design targeting vulnerable populations. In this study, we employed proteomics to characterize the adjuvant-induced changes of secretomes from human new ...[more]

PMID: 26933193

Similar Datasets

Project description:Terminalia arjuna (Roxb.) Wight & Arn., a well known Traditional medicine an. popularly known as Arjuna, has a long antiquity of its role as a cardiac stimulant, and has been stipulated in the treatment of hypercholesterolemia, heart failure and atherosclerosis. The present study was carried out to access the effects of Terminalia arjuna as an adjuvant therapy in angiographically proven patients with stable coronary artery disease who were on conventional medications. The goal of the study was to establish whether Terminalia arjuna exerts beneficial effects in targetting disease signatures which remain unresponsive to the standard therapies currently employed in the clinics. The present study scientifically validates the therapeutic effects of this medicinal plant as an adjuvant therapy along with conventional drugs routinely used in the clinics for prevention and treatment of coronary artery disease. To access the effect of T.arjuna, a placebo-controlled, double blind randomized study was carried out in 100 angiographically proven non-diabetic patients with coronary artery disease having disease more than 3 months prior to their enrollment and using any combination of cardiac-related medications including ASA, ACEIs, ARBs, β-blockers and statins (Trial Registration Number : REF/2013/03/004810). Out of total 100 patients, 50 patients were on drug A and 50 patients were on drug B for a total duration of 6 months (Follow-up at 3 and 6 months). Both Drug as well as placebo was given in the form of capsule (500mg) provided by The Himalaya Drug Company, Bangalore. Method of concealment was through coded identical containers. All the participants, investigator, outcome Assessor and data-entry operator were blinded during the whole study. Micro-array was performed in 2 randomly selected patients in each sub-group i.e. Terminalia arjuna or Placebo at 3 and 6 months respectively. RNA extraction and hybridization was carried out using Affymetrix microarrays. Differential expression of genes in T.arjuna-treated and Placebo groups was studied to understand the specificity, efficacy and mechanism of action of T.arjuna.

Dataset Information

Adjuvant Secretomes - Adjuvant-induced human monocyte secretome profiles reveal adjuvant- and age-specific protein signatures

Publications

Adjuvant-induced Human Monocyte Secretome Profiles Reveal Adjuvant- and Age-specific Protein Signatures.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure